Scientific Articles
Zoe X. Malchiodi, Alexander A. Lekan, Robert K. Suter, Atul Deshpande, Selime Arslan, Annabel J. Lee, Nuan Wang, Ivana Peran, Brent T. Harris, Anju Duttargi, Min-Ju Chien, Samika Hariharan, Lucia Wetherill, Sandra A. Jablonski, Won Jin Ho, Marwa Afifi, Elana J. Fertig, Louis M. Weiner; Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer. Cancer Immunol Res (2026); https://doi.org/10.1158/2326-6066.CIR-25-1481
Molotkova A, Deniz E, Swift M, Glasgow E, Ma J, Petro JA, Frye I, Ozdemirli M, Pesic D, Ahern GP, Suter RK, Tiwari PB, Shlien A, Toretsky J, Üren A. ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis. Cancer Res Commun. (2026) Mar 1;6(3):477-499. doi: 10.1158/2767-9764.CRC-26-0068. PMID: 41650465; PMCID: PMC13012068.
Suter, R.K., Jermakowicz, A.M., Veeramachaneni, R. et al. Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations. Nat Commun 17, 99 (2026). https://doi.org/10.1038/s41467-025-67783-5
Anna M Jermakowicz, Luz Ruiz, Jonathan Chu, Nitish Jangde, Robert K Suter, Nina S Kadan-Lottick, Derek Hanson, Nagi G Ayad. In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients. Sci Rep 15, 42373 (2025). https://doi.org/10.1038/s41598-025-26411-4
Fahda Alsharief, Robert K Suter, Apsra Nasir, Gray W. Pearson. Multiple distinct metastatic cell states are induced by epithelial-mesenchymal plasticity. bioRxiv 2025.08.15.670583; doi: https://doi.org/10.1101/2025.08.15.670583
Matthew D’Antuono, Madison Sharp, Rishika Chowdary, Michael E. Ivan, Ricardo J. Komotar, Robert K. Suter, Nagi G. Ayad. Identification of disease-specific vulnerability states at the single-cell level. bioRxiv 2024.12.04.626873; doi: https://doi.org/10.1101/2024.12.04.626873
Rishika Chowdary, Robert K. Suter, Matthew D’Antuono, Cynthia Gomes, Joshua Stein, Ki-Bum Lee, Jae K Lee, Nagi G. Ayad. OrthologAL: A Shiny application for quality-aware humanization of non-human pre-clinical high-dimensional gene expression data. bioRxiv 2024.11.25.625000; doi: https://doi.org/10.1101/2024.11.25.625000
Veeramachaneni RK, Suter RK, Rowland E, Jermakowicz A, Ayad NG. Glutaminase 2 as a therapeutic target in glioblastoma. Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189182. doi: 10.1016/j.bbcan.2024.189182. Epub 2024 Sep 16. PMID: 39293549.
Rodriguez-Blanco, J. Salvador, AD, Suter RK, Swiderska-Syn, M, Palomo-Caturla, I, Vieira, ME, Wynn, DT, Nienhius, AM, Yang, F, Ban, Y McCrea, HJ, Zindy, F, Danis, EP, Martin, V, Barnoud, T, De Cubas, A, Chen, SX, Roussel, MF, Ayad, NG, Robbins, DJ. Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models. J Clin Invest. 2024 Jun 17;134(15):e171136. doi: 10.1172/JCI171136. PMID: 38885332; PMCID: PMC11290968.
Malchiodi ZX, Suter RK, Desphande A, Peran I, Harris BT, Duttargi A, Chien MJ, Hariharan S, Wetherill L, Jablonski SA, Ho WJ, Fertig EJ, Weiner LM. Natural killer cells associate with epithelial cells in the pancreatic ductal adenocarcinoma tumor microenvironment. 2024 BioRxiv, Pre-Print
Walter TJ, Suter RK, Ayad NG. An overview of human single-cell RNA sequencing studies in neurobiological disease. Neurobiology of Disease. Volume 184, 2023, 106201, ISSN 0969-9961, https://doi.org/10.1016/j.nbd.2023.106201. (https://www.sciencedirect.com/science/article/pii/S0969996123002164)
Shah AH, Rivas SR, Doucet-O'Hare TT, Govindarajan V, DeMarino C, Wang T, Ampie L, Zhang Y, Banasavadi-Siddegowda YK, Walbridge S, Maric D, Garcia-Montojo M, Suter RK, Lee MH, Zaghloul KA, Steiner J, Elkahloun AG, Chandar J, Seetharam D, Desgraves J, Li W, Johnson K, Ivan ME, Komotar RJ, Gilbert MR, Heiss JD, Nath A. Human endogenous retrovirus K contributes to a stem cell niche in glioblastoma. J Clin Invest. 2023 Jul 3;133(13):e167929. doi: 10.1172/JCI167929. PMID: 37395282; PMCID: PMC10313366.
Yang F, Rodriguez-Blanco J, Long J, Swiderska-Syn M, Wynn DT, Li B, Shen C, Nayak A, Ban Y, Sun X, Suter RK, McCrea H, Capobianco AJ, Ayad NG, Robbins DJ (2022). A druggable UHRF1/DNMT1/GLI complex regulated Sonic hedgehog dependent tumor growth. Mol Cancer Res. 2022 Aug 4:MCR-22-0182. doi: 10.1158/1541-7786.MCR-22-0182. Epub ahead of print. (PMID: 35925047)
Govindarajan V, Shah AH, Di L, Rivas S, Suter RK, Eichberg DG, Luther E, Lu V, Morell AA, Ivan ME, Ricardo J. Komotar, Nagi Ayad, Macarena De La Fuente (2022). Systematic review of epigenetic therapies for treatment of IDH-mutant glioma. World Neurosurgery 162:47-56. doi: 10.1016/j.wneu.2022.03.051. Epub 2022 Mar 18. (PMID: 35314408; PMCID: PMC9177782)
Rybin M, Laverde-Paz MJ, Suter RK, Affer M, Ayad NG, Feng Y, Zeier Z (2022). A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion. Bioorganic & Medicinal Chemistry Letters 2022 Apr 1;61:128614. doi: 10.1016/j.bmcl.2022.128614. Epub 2022 Feb 10. (PMID: 35151865)
Shah AH, Suter RK, Gudoor P, Doucet-O'Hare TT, Stathias V, Cajigas I, de la Fuente M, Govindarajan V, Morell AA, Eichberg DG, Luther E, Lu VM, Heiss J, Komotar RJ, Ivan ME, Schurer S, Gilbert MR, Ayad NG. (2022) A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines. Neuro-Oncology Advances 4(1):vdab192. doi: 10.1093/noajnl/vdab192. eCollection 2022 Jan-Dec. (PMID: 35118385)
Jermakowicz AM, Suter RK, Rybin M, … Ayad NG (2021). The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion. Scientific Reports 11(1):23370. doi: 10.1038/s41598-021-02584-6. (PMID: 34862404; PMCID: PMC8642539)
Suter RK, Rodriguez-Blanco J, Ayad NG (2020) Epigenetic pathways and plasticity in brain tumors. Neurobiology of Disease 145:105060. doi: 10.1016/j.nbd.2020.105060. Epub 2020 Aug 30. (PMID: 32877743)
Stathias V., Jermakowicz AM, Maloof ME, Forlin M, Walters W, Suter RK, … & Ayad NG (2018). Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nature Communications 9(1):5315. doi: 10.1038/s41467-018-07659-z. (PMID: 30552330)
Conference Presentations & Posters
Suter RK, Stathias V, Jermakowicz AM, Semonche A, Ivan M, Komotar R, Schürer S, Ayad NG (2019). Comprehensive transcriptomic analysis of single cells from recurrent and primary glioblastoma to predict cell-type specific therapeutics. Neuro-Oncology 21(Suppl 6):vi64. doi: 10.1093/neuonc/noz175.259. Epub 2019 Nov 11. (PMCID: PMC6847438)
Jermakowicz AM, Stathias V, Suter RK, Duncan J, Schürer S, Ayad NG (2019). Integrating transcriptomics and kinomics identifies synergistic drug combinations for glioblastoma treatment. Neuro-Oncology 21(Suppl 6):vi105. doi: 10.1093/neuonc/noz175.438. Epub 2019 Nov 11. (PMCID: PMC6846862)
Suter RK, Stathias V, Jermakowicz AM, Pradhyumnan H, Affer M, Guglielmetti F, Ivan M, Komotar R, De la Fuente M, Sarkaria J, Schurer S, Ayad NG (2021). A mesenchymal cell population mediates resistance to aurora kinase inhibitors in glioblastoma. Neuro-Oncology , Volume 23, Issue Supplement_6, November 2021, Page vi5, https://doi.org/10.1093/neuonc/noab196.017
Ayad N, Suter RK, Robbins D, Roussel M (2020) BET Bromodomain protein-kinase inhibitor combinations for the treatment of medulloblastoma. Neuro-Oncology 22(Suppl 3):iii399. doi: 10.1093/neuonc/noaa222.523. (PMCID: PMC7715348)